报价延迟最少15分钟:2026/04/15 09:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.81/-0.01
|
|
企业价值
97.11M
|
| 资产负债 |
|
每股账面净值
0.30
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
65.34K
|
|
每股收益
0.12
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP. |
